Dreamtech distributes Cardea SOLO™ ECG System in Korea through its latest healthcare organization, iSigNal, and leads commercial expansion in 20+ other APAC countries.
US-based Cardiac Insight takes up a distribution deal to enter the APAC market.
American medical device maker Cardiac Insight specializing in wearable cardiac sensors and automated ECG analysis software, announced today that it has collaborated with i.SigNal, The digital health chain of South Korean technology firm Dreamtech. I.SigNal distributes Cardea SOLO. A single-use vestured ECG patch and its proprietary analysis software system in 23 APAC nations.
Cardiac Insight’s ECG patch and analysis software combine to provide speedy, in-clinic automated cardiac analysis and reporting. It delivers a standalone solution that does not need internet access, cloud computing solutions, or third-party outsourcing.
Cardiac Insight CEO Brad Harlow said in the latest release, “Our global distributive partnership with i.SigNal is a key alliance for the company, integrating our high-quality ECG technology with i.SigNal’s strategic healthcare market hub that will accelerate the adoption of the Cardea SOLO System on a global scale”.
Dreamtech CEO Min Kim said, “Cardiac Insight’s market-disrupting ECG patch technology provides a compelling advantage to Korea and Asia-Pacific markets. It helps physicians to improve the detection, prognosis, and therapy of dangerous cardiac arrhythmias. The diseases include atrial fibrillation that, left uncured, can lead to disabling stroke, heart failure, and death. The device is recognized to maximize the hospital and clinic staff productivity per ECG test while keeping valuable patient data within the healthcare institution for enhanced data privacy, security, and cost-effectiveness.”
Dreamtech’s i.SigNal gained a medical device license for Cardea SOLO from the Korean Ministry of Food and Drug Safety last year. It continues acquiring regulatory approvals and conducts distributive activities in the Asia-Pacific market.